These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

109 related items for PubMed ID: 21556716

  • 1. Maintenance therapy with mycophenolate mofetil after rituximab in pediatric patients with steroid-dependent nephrotic syndrome.
    Ito S, Kamei K, Ogura M, Sato M, Fujimaru T, Ishikawa T, Udagawa T, Iijima K.
    Pediatr Nephrol; 2011 Oct; 26(10):1823-8. PubMed ID: 21556716
    [Abstract] [Full Text] [Related]

  • 2. Rituximab in childhood steroid-sensitive nephrotic syndrome: are multiple subsequent courses safe and effective?
    Subun C, Suwannahitatorn P, Webb H, Tullus K.
    Arch Dis Child; 2021 Jul 19; 106(8):815-818. PubMed ID: 33177054
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of long-term repeated use of rituximab in pediatric patients with nephrotic syndrome.
    Choi N, Min J, Kim JH, Kang HG, Ahn YH.
    Pediatr Nephrol; 2024 Mar 19; 39(3):771-780. PubMed ID: 37682369
    [Abstract] [Full Text] [Related]

  • 4. Rituximab for nephrotic syndrome in children.
    Iijima K, Sako M, Nozu K.
    Clin Exp Nephrol; 2017 Apr 19; 21(2):193-202. PubMed ID: 27422620
    [Abstract] [Full Text] [Related]

  • 5. Adverse events linked with the use of chimeric and humanized anti-CD20 antibodies in children with idiopathic nephrotic syndrome.
    Bonanni A, Calatroni M, D'Alessandro M, Signa S, Bertelli E, Cioni M, Di Marco E, Biassoni R, Caridi G, Ingrasciotta G, Bertelli R, Di Donato A, Bruschi M, Canepa A, Piaggio G, Ravani P, Ghiggeri GM.
    Br J Clin Pharmacol; 2018 Jun 19; 84(6):1238-1249. PubMed ID: 29436729
    [Abstract] [Full Text] [Related]

  • 6. Obinutuzumab in Frequently Relapsing and Steroid-Dependent Nephrotic Syndrome in Children.
    Dossier C, Bonneric S, Baudouin V, Kwon T, Prim B, Cambier A, Couderc A, Moreau C, Deschenes G, Hogan J.
    Clin J Am Soc Nephrol; 2023 Dec 01; 18(12):1555-1562. PubMed ID: 37678236
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of mycophenolate mofetil for steroid reduction in neuromyelitis optica spectrum disorder: a prospective cohort study.
    Akatani R, Chihara N, Koto S, Mori S, Kurimoto T, Nakamura M, Tachibana H, Otsuka Y, Ueda T, Omori T, Sekiguchi K, Matsumoto R.
    Immunol Med; 2024 Jun 01; 47(2):85-92. PubMed ID: 38235761
    [Abstract] [Full Text] [Related]

  • 8. The Efficacy and Safety of Rituximab for Childhood Steroid-Dependent Nephrotic Syndrome: A Systematic Review and Meta-Analysis.
    Liu S, Gui C, Lu Z, Li H, Fu Z, Deng Y.
    Front Pediatr; 2021 Jun 01; 9():728010. PubMed ID: 34490171
    [Abstract] [Full Text] [Related]

  • 9. Immunosuppression for adult steroid-dependent or frequently relapsing nephrotic syndrome: A systematic review and meta-analysis.
    Wong ZY, Teo CY, Fiona Wong YQ, Ng KT, Lim SK.
    PLoS One; 2024 Jun 01; 19(7):e0307981. PubMed ID: 39083488
    [Abstract] [Full Text] [Related]

  • 10. Rituximab in Steroid-Dependent Podocytopathies.
    Costa C, Antunes A, Oliveira J, Pereira M, Godinho I, Fernandes P, Jorge S, Lopes JA, Gameiro J.
    Glomerular Dis; 2024 Jun 01; 4(1):129-136. PubMed ID: 39144474
    [Abstract] [Full Text] [Related]

  • 11. A case diagnosed with IgA nephropathy during a complete remission of minimal change nephrotic syndrome treated with rituximab.
    Nishikawa M, Shimada N, Kurahashi M, Watanabe K, Kanzaki M, Fukuoka K, Asano K.
    CEN Case Rep; 2024 May 22. PubMed ID: 38775892
    [Abstract] [Full Text] [Related]

  • 12. Effectiveness and safety of mycophenolate mofetil and rituximab combination therapy for immune idiopathic myopathies.
    Campochiaro C, Farina N, De Luca G, Batani V, Trignani G, Vignale D, Palmisano A, Matucci-Cerinic M, Dagna L.
    Arthritis Res Ther; 2024 Apr 03; 26(1):79. PubMed ID: 38570792
    [Abstract] [Full Text] [Related]

  • 13. Timing and selection of steroid-sparing agents for children with early-stage steroid-sensitive nephrotic syndrome.
    Fujinaga S.
    Pediatr Nephrol; 2024 Aug 03; 39(8):2539. PubMed ID: 38411639
    [No Abstract] [Full Text] [Related]

  • 14. Japanese clinical practice patterns of rituximab treatment for minimal change disease in adults 2021: A web-based questionnaire survey of certified nephrologists.
    Koizumi M, Ishimoto T, Shimizu S, Sasaki S, Kurita N, Wada T.
    PLoS One; 2024 Aug 03; 19(3):e0299053. PubMed ID: 38551948
    [Abstract] [Full Text] [Related]

  • 15. Survey of rituximab treatment for childhood-onset refractory nephrotic syndrome.
    Ito S, Kamei K, Ogura M, Udagawa T, Fujinaga S, Saito M, Sako M, Iijima K.
    Pediatr Nephrol; 2013 Feb 03; 28(2):257-64. PubMed ID: 23052656
    [Abstract] [Full Text] [Related]

  • 16. Positive role of rituximab in switching from cyclosporine to mycophenolate mofetil for children with high-dose steroid-dependent nephrotic syndrome.
    Fujinaga S, Sakuraya K, Yamada A, Urushihara Y, Ohtomo Y, Shimizu T.
    Pediatr Nephrol; 2015 Apr 03; 30(4):687-91. PubMed ID: 25576066
    [Abstract] [Full Text] [Related]

  • 17. Novel use of rituximab for steroid-dependent nephrotic syndrome in children.
    Kimata T, Hasui M, Kino J, Kitao T, Yamanouchi S, Tsuji S, Kaneko K.
    Am J Nephrol; 2013 Apr 03; 38(6):483-8. PubMed ID: 24296765
    [Abstract] [Full Text] [Related]

  • 18. Atypical Pneumocystis jiroveci pneumonia with multiple nodular granulomas after rituximab for refractory nephrotic syndrome.
    Sato M, Ito S, Ogura M, Kamei K, Miyairi I, Miyata I, Higuchi M, Matsuoka K.
    Pediatr Nephrol; 2013 Jan 03; 28(1):145-9. PubMed ID: 22948319
    [Abstract] [Full Text] [Related]

  • 19. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial.
    Iijima K, Sako M, Nozu K, Mori R, Tuchida N, Kamei K, Miura K, Aya K, Nakanishi K, Ohtomo Y, Takahashi S, Tanaka R, Kaito H, Nakamura H, Ishikura K, Ito S, Ohashi Y, Rituximab for Childhood-onset Refractory Nephrotic Syndrome (RCRNS) Study Group.
    Lancet; 2014 Oct 04; 384(9950):1273-81. PubMed ID: 24965823
    [Abstract] [Full Text] [Related]

  • 20. Cyclosporine versus mycophenolate mofetil for maintenance of remission of steroid-dependent nephrotic syndrome after a single infusion of rituximab.
    Fujinaga S, Someya T, Watanabe T, Ito A, Ohtomo Y, Shimizu T, Kaneko K.
    Eur J Pediatr; 2013 Apr 04; 172(4):513-8. PubMed ID: 23271494
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.